source
- Big pharma Q3 earnings roll out as FDA launches rare-disease initiative and uniQure's Huntington's gene therapy enters reviewOver the past week, a dozen major pharmaceutical companies reported third‑quarter results, including AstraZeneca, Biogen, GSK, Bristol Myers Squibb, Merck, Sanofi, AbbVie and Regeneron. Pfizer pos…
- Sanofi halts development of Nurix-partnered STAT6 degrader, triggering sharp drop in Nurix stockSanofi announced it is ending work on SAR448272, an experimental oral drug that was intended to degrade the STAT6 protein, which is linked to inflammatory diseases. The biotech firm Nurix, which l…